Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Markets Rattle as India-Pakistan Border Tensions Escalate; Gift Nifty Signals Gap-Down Open
The Gift Nifty is signaling a weak opening for Indian markets, trading around 23,974—nearly 298 points below the Nifty futures’ previous close. This decline comes amid heightened geopolitical tensions, as Pakistani drones...
Discussion about this post